As of Oct 26, 2026: BridgeBio Pharma (BBIO) has a PDUFA date for BBP-418 on Nov 27, 2026, in 32 days. Its Quality Score is 3. Scores as of 8:36 PM ET, 15 minutes behind.

BBIO FDA decision on BBP-418

BridgeBio Pharma · PDUFA date

PDUFA dateNov 27in 32 days Quality Score3Below Average

Cash runway6quarters of cash

What the company said

“three planned NDAs are now submitted to the FDA: BBP-418 for LGMD2I/R9 was accepted with Priority Review (PDUFA November 27, 2026)”

PDUFA date, Nov 27, 2026. As BridgeBio Pharma stated in its 8-K of Aug 10, 2026 (the filing).

A PDUFA date is the day the FDA has said it aims to decide on a drug. The FDA can decide earlier, or extend its review, often by three months.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Get an alert before BBIO's FDA date

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

How BBIO's stock moved on its past FDA days, for Pro members. Pro members also see whether its cash lasts past Nov 27, and the members' FDA calendar with filters and optional alerts.

More on BBIO and the FDA calendar

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

The FDA calendar.